Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | THRA | P10827 | 5/20 | 0.52 |
| ▸ | THRB | P10828 | 5/20 | 0.52 |
| ▸ | EGLN2 | Q96KS0 | 15/20 | 0.48 |
| ▸ | EGLN1 | Q9GZT9 | 14/20 | 0.48 |
| ▸ | BBOX1 | O75936 | 1/20 | 0.45 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.45 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.45 |
| ▸ | ASPH | Q12797 | 1/20 | 0.45 |
| ▸ | KDM8 | Q8N371 | 1/20 | 0.45 |
| ▸ | FTO | Q9C0B1 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13601817 | 0.85 | EGLN1 (0.59) | THRATHRBEGLN2EGLN1BBOX1 | |
| SCHEMBL522869 | 0.82 | EGLN2 (0.58) | THRATHRBEGLN2EGLN1 | |
| SCHEMBL523581 | 0.82 | EGLN2 (0.58) | THRATHRBEGLN2EGLN1 | |
| SCHEMBL5380536 | 0.82 | EGLN2 (0.49) | THRATHRBEGLN2EGLN1BBOX1 | |
| SCHEMBL5454600 | 0.82 | EGLN2 (0.49) | THRATHRBEGLN2EGLN1BBOX1 | |
| SCHEMBL522868 | 0.82 | EGLN2 (0.58) | THRATHRBEGLN2EGLN1 | |
| SCHEMBL5454614 | 0.82 | EGLN2 (0.49) | THRATHRBEGLN2EGLN1BBOX1 | |
| SCHEMBL526495 | 0.80 | EGLN2 (0.57) | THRATHRBEGLN2EGLN1 | |
| SCHEMBL13601810 | 0.79 | EGLN2 (0.58) | EGLN2EGLN1 | |
| SCHEMBL13601814 | 0.77 | EGLN1 (0.52) | THRATHRBEGLN2EGLN1BBOX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7629357-B2 | Antihypoxic agents; adjust concentration of erythropoietin concentration in blood; strokes; antiepileptic agents; neurodegenerative disease ; liver disorders; antiischemic agents | FIBROGEN, INC. (US) | 2009-12-08 | — | — | US | disclosed |
| US-7629357-B2 | Antihypoxic agents; adjust concentration of erythropoietin concentration in blood; strokes; antiepileptic agents; neurodegenerative disease ; liver disorders; antiischemic agents | FIBROGEN, INC. (US) | 2009-12-08 | — | — | US | disclosed |